logo-loader

IPO Roundup: NASH treatment developer 89bio makes its public debut after $85M IPO

The company offered 5.3 million shares, 900,000 more than originally planned

Colorfully written IPO with arrows pointing to the letters
The company’s lead product candidate, BIO89-100, is an engineered analog of fibroblast growth factor 21 designed to treat non-alcoholic steatohepatitis

89bio Inc (NASDAQ:ETNB), a Phase 1 biotechnology company developing therapies for non-alcoholic steatohepatitis (NASH), raised $85 million in an upsized IPO following a short delay. 

Last week, the San Francisco company opted to postpone its IPO after an administrative issue arose between its auditor and the SEC.

READ: IPO Roundup: NASH treatment developer 89bio ready to go public following brief IPO delay

89bio ended up offering 5.3 million shares, 900,000 more than planned, at $16 per share, the midpoint of its $15 to $17 range.

The company’s lead product candidate, BIO89-100, is an engineered analog of fibroblast growth factor 21, which functions as an endocrine hormone-regulating carbohydrate and lipid metabolism.

89bio stock opened trading at $20 on Monday, where it remains on Wednesday, 25% above its IPO price.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Empower Clinics reformulates Sollievo product line to...

Empower Clinics (CSE: CBDT-OTC: EPWCF) Chairman and CEO Steven McAuley joined Steve Darling in the Vancouver studio of Proactive to bring news the company has launched a series of re-formulated versions of its CBD tincture product line Sollievo. McAuley talks about why they did it and how...

10 hours, 13 minutes ago

2 min read